How to Help Your Patients Find Imvexxy in Stock: A Provider's Guide

Patients prescribed Imvexxy (estradiol vaginal inserts) for menopausal dyspareunia increasingly report difficulty finding the medication at their local pharmacy. While this isn't a formal FDA shortage, prescribers play a critical role in helping patients navigate the access challenges and avoid treatment interruptions. This guide provides concrete, actionable strategies you can implement in your practice.

Why Patients Can't Find Imvexxy at Their Pharmacy

Before you can help patients, it helps to understand the root causes. Imvexxy availability issues stem from several structural factors:

• Limited retail stocking: Pharmacies stock medications based on demand. Imvexxy's brand-only status (until December 2025) and high cost reduce its prescription volume, meaning many pharmacies don't stock it.
• Insurance barriers: Most Medicare Part D plans don't cover Imvexxy. Commercial plans often require prior authorization and step therapy. This reduces patient traffic to retail pharmacies for this specific product.
• Generic transition: The December 2025 FDA approval of generic estradiol vaginal inserts may lead some pharmacies to shift ordering toward the generic and away from the brand.

Strategy #1: Write Prescriptions by Generic Name to Maximize Flexibility

Rather than writing "Imvexxy 4 mcg" or "Imvexxy 10 mcg," consider writing the generic name: "estradiol vaginal inserts 4 mcg" or "estradiol vaginal inserts 10 mcg." This allows the dispensing pharmacist to fill with whatever product — brand or generic — is currently in stock. With the December 2025 generic approval, this flexibility will become increasingly valuable.

Note: If you have a specific clinical reason to require the brand (e.g., the patient has tried and preferred the Imvexxy softgel formulation over the generic), use DAW-1 (Dispense as Written) notation and document the clinical rationale.

Strategy #2: Direct Patients to medfinder for Pharmacy Locating

medfinder is a prescription locator service that calls pharmacies near a patient's location to find which ones currently have a specific medication in stock. Prescribers can incorporate medfinder into their patient workflow by directing patients to medfinder.com/providers to learn how to add it to your practice. This reduces the back-and-forth of patients calling multiple pharmacies and returning to your office unable to fill their prescription.

Strategy #3: Know the Savings Programs Available to Your Patients

When cost is the barrier, equip your patients with this information:

• Imvexxy Savings Card (Mayne Pharma): Commercially insured patients can reduce their out-of-pocket cost to as little as $35 per prescription. Available at imvexxy.com/savings-information.
• GoodRx coupons: GoodRx offers coupons for Imvexxy at as low as $50 per pack at participating pharmacies, an 81% reduction from the retail price of ~$263 per maintenance pack.
• SingleCare: SingleCare offers discounts on Imvexxy starter and maintenance packs. Can be used with or without insurance.

Strategy #4: Streamline Prior Authorization Documentation

Prior authorization is one of the most common barriers to Imvexxy access. Prepare your PA documentation in advance with these elements:

• Diagnosis: Moderate to severe dyspareunia due to vulvar and vaginal atrophy/GSM secondary to menopause
• Rationale for insert formulation over cream or ring alternatives
• Prior therapy documentation if step therapy is required (e.g., trial of generic vaginal estrogen cream)
• Justification for 4 mcg dose if that specific strength is required (note: standard generic estradiol vaginal tablets are 10 mcg only)

Strategy #5: Consider Mail-Order Options for Ongoing Maintenance

For patients who are stable on maintenance therapy (1 insert twice weekly), mail-order prescriptions reduce the burden of repeated trips to pharmacies that may not stock Imvexxy. When writing the prescription, note that a 90-day supply may be dispensed via mail order. Alert patients that mail-order prescriptions may require a separate written prescription and prior insurance approval for a 90-day quantity.

Strategy #6: Offer Telehealth Follow-Up for Prescription Adjustments

If a patient calls or messages to report they cannot fill their Imvexxy prescription, avoid requiring an in-office visit simply to switch formulations or write a new prescription. A brief telehealth encounter is usually sufficient to adjust therapy, write for the generic, or provide a bridge prescription. This improves patient retention and reduces treatment gaps.

A Note on Patient Communication

Many patients experiencing difficulty finding Imvexxy feel dismissed or invalidated when told "there's no shortage." Acknowledge their experience, explain the structural reasons for the access issues, and give them concrete tools. Printing or emailing a list of options — including medfinder, savings cards, and pharmacies likely to carry or order Imvexxy — is often more effective than a verbal conversation. For more clinical detail on this topic, see our provider briefing on Imvexxy availability in 2026.